Literature DB >> 25063221

MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression.

Ruixin Li1, Weijie Yuan, Wenjuan Mei, Keda Yang, Zihua Chen.   

Abstract

Aberrant expression of microRNAs (miRNAs) has been shown to play important roles in cancer progression as a result of changes in expression of their target genes. In this study, we investigated the roles of miR-520d-3p on gastric cancer (GC) cell proliferation, migration, and invasion, and confirmed that this miRNA regulates EphA2 expression. The mRNA expression levels of miR-520d-3p and EphA2 in GC tissues and cell lines were evaluated. The clinical and prognostic significance of miR-520d-3p was assessed. The biological function of miR-520d-3p in GC cells was investigated using a methylthiazolyldiphenyl-tetrazolium bromide assay, cell cycle assay, transwell invasion assay, and wound-healing assay. miR-520d-3p expression was down-regulated and inversely correlated with the expression of EphA2 in GC tissues and cell lines. Lower expression of miR-520d-3p was associated with tumor invasion (P = 0.0357), lymph nodes metastasis (P = 0.0272), a higher clinical stage (P = 0.0041), and poorer overall survival (P = 0.0105). Luciferase assays revealed that miR-520d-3p inhibited EphA2 expression by targeting the 3'-untranslated region of EphA2 mRNA. Overexpression of miR-520d-3p dramatically inhibited the proliferation, cell cycle progression, invasion, and migration of GC cells, while down-regulation substantially promoted these properties. Moreover, c-Myc, CyclinD1, and matrix metalloproteinase-9 expression levels were down-regulated in miR-520d-3p mimic-transfected cells and up-regulated in miR-520d-3p inhibitor-transfected cells. Taken together, our data showed that miR-520d-3p appears to contribute to GC progression via the regulation of EphA2 and could serve as a novel prognostic and potential therapeutic marker.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25063221     DOI: 10.1007/s11010-014-2164-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  36 in total

1.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Authors:  Masato Nishimura; Eun-Jung Jung; Maitri Y Shah; Chunhua Lu; Riccardo Spizzo; Masayoshi Shimizu; Hee Dong Han; Cristina Ivan; Simona Rossi; Xinna Zhang; Milena S Nicoloso; Sherry Y Wu; Maria Ines Almeida; Justin Bottsford-Miller; Chad V Pecot; Behrouz Zand; Koji Matsuo; Mian M Shahzad; Nicholas B Jennings; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; George A Calin
Journal:  Cancer Discov       Date:  2013-09-03       Impact factor: 39.397

2.  Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family.

Authors:  Fengju Song; Da Yang; Ben Liu; Yan Guo; Hong Zheng; Lian Li; Tao Wang; Jinpu Yu; Yanrui Zhao; Ruifang Niu; Han Liang; Hans Winkler; Wei Zhang; Xishan Hao; Kexin Chen
Journal:  Clin Cancer Res       Date:  2013-12-18       Impact factor: 12.531

3.  The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors.

Authors:  H C Crawford; B M Fingleton; L A Rudolph-Owen; K J Goss; B Rubinfeld; P Polakis; L M Matrisian
Journal:  Oncogene       Date:  1999-05-06       Impact factor: 9.867

4.  Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.

Authors:  Masashi Ishikawa; Ryo Miyahara; Makoto Sonobe; Marika Horiuchi; Toshi Mennju; Ei Nakayama; Masashi Kobayashi; Ryutaro Kikuchi; Jiro Kitamura; Naoto Imamura; Cheng-Long Huang; Hiroshi Date
Journal:  Lung Cancer       Date:  2012-01-10       Impact factor: 5.705

5.  Identification of c-MYC as a target of the APC pathway.

Authors:  T C He; A B Sparks; C Rago; H Hermeking; L Zawel; L T da Costa; P J Morin; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1998-09-04       Impact factor: 47.728

6.  Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis.

Authors:  Weijie Yuan; Zhikang Chen; Shaobin Wu; Jie Ge; Shi Chang; Xianwei Wang; Jingxiang Chen; Zihua Chen
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

7.  EphA2 overexpression promotes ovarian cancer growth.

Authors:  Chunhua Lu; Mian M K Shahzad; Hua Wang; Charles N Landen; Seung W Kim; Julie Allen; Alpa M Nick; Nicholas Jennings; Michael S Kinch; Menashe Bar-Eli; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2008-04-19       Impact factor: 4.742

8.  Expression of EphA2 in human astrocytic tumors: correlation with pathologic grade, proliferation and apoptosis.

Authors:  Xia Li; Yingmei Wang; Yazhou Wang; Haining Zhen; Hao Yang; Zhou Fei; Jianning Zhang; Weiping Liu; Yangang Wang; Xiang Zhang
Journal:  Tumour Biol       Date:  2007-05-21

Review 9.  MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers.

Authors:  Jee Hoon Song; Stephen J Meltzer
Journal:  Gastroenterology       Date:  2012-05-10       Impact factor: 22.682

10.  MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer.

Authors:  Ji-Young Shin; Young-Il Kim; Soo-Jeong Cho; Mi Kyung Lee; Myeong-Cherl Kook; Jun Ho Lee; Sang Soo Lee; Hassan Ashktorab; Duane T Smoot; Keun Won Ryu; Young-Woo Kim; Il Ju Choi
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more
  21 in total

1.  Role of microRNAs in diagnosis and treatment of the pathogenesis of gastric cancer.

Authors:  Gang Chen; Yong Tang; Jiang-Hua Wu; Feng-Hua Liu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Oxidative stress response and Nrf2 signaling in aging.

Authors:  Hongqiao Zhang; Kelvin J A Davies; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2015-06-09       Impact factor: 7.376

3.  SP1-mediated microRNA-520d-5p suppresses tumor growth and metastasis in colorectal cancer by targeting CTHRC1.

Authors:  Li Yan; Jiang Yu; Fei Tan; Geng-Tai Ye; Zhi-Yong Shen; Hao Liu; Yan Zhang; Jie-Fu Wang; Xian-Jun Zhu; Guo-Xin Li
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

4.  MicroRNA-541 promotes the proliferation of vascular smooth muscle cells by targeting IRF7.

Authors:  Fang Yang; Zonglei Xu; Shaobin Duan; Min Luo
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

5.  SIRP Alpha Protein Downregulates in Human Astrocytoma: Presumptive Involvement of Hsa-miR-520d-5p and Hsa-miR-520d-3p.

Authors:  Ravindra Pramod Deshpande; Y B V K Chandra Sekhar; Manas Panigrahi; Phanithi Prakash Babu
Journal:  Mol Neurobiol       Date:  2016-11-29       Impact factor: 5.590

6.  MiR-520d-3p antitumor activity in human breast cancer via post-transcriptional regulation of spindle and kinetochore associated 2 expression.

Authors:  Zhouhui Ren; Tong Yang; Jie Ding; Weihong Liu; Xiangyu Meng; Pingping Zhang; Kaitai Liu; Ping Wang
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

7.  MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2.

Authors:  Hesheng Li; Qinglei Sun; Bing Han; Xingquan Yu; Baoguang Hu; Sanyuan Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

8.  miR-488 acts as a tumor suppressor gene in gastric cancer.

Authors:  Yan Zhao; Guifang Lu; Xiquan Ke; Xinlan Lu; Xin Wang; Hongxia Li; Mudan Ren; Shuixiang He
Journal:  Tumour Biol       Date:  2016-01-06

Review 9.  Dysregulation of non-coding RNAs in gastric cancer.

Authors:  Qing Yang; Ren-Wen Zhang; Peng-Cheng Sui; Hai-Tao He; Lei Ding
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis.

Authors:  Linfeng Mao; Weijie Yuan; Kaimei Cai; Chen Lai; Changhao Huang; Yi Xu; Shangwei Zhong; Chen Yang; Ran Wang; Pengwei Zeng; Heyuan Huang; Zhikang Chen; Zihua Chen
Journal:  Oncogene       Date:  2021-05-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.